What Happened?
Boston, MA-based Pieris-Pharmaceuticals Appointed Stephen Yoder as President and Chief Executive Officer
About the Company
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
About the Person
Stephen Yoder is President and Chief Executive Officer at Pieris Pharmaceuticals. Previously, Stephen held various senior HR leadership roles in the industry.
Info Source
News
Short Profile